Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease

Fig. 3

Effect of human bmMSC, ucMSC, kPSC or CM-ucMSC infusions on renal fibrosis and glomerulosclerosis. a Quantification of fibronectin deposits along Bowman’s capsule in control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 28 days. Score between 0 and 3 assigned by evaluating thickness of Bowman’s capsule. Data are mean ± SE. ***p < 0.001 vs control; °p < 0.05 and °°p < 0.01 vs ADR + saline. b Representative images showing fibronectin expression in renal sections of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 28 days. Scale bar 20 μm. c Quantification of glomeruli affected by sclerotic lesions (%GS) assessed in PAS-stained kidney sections of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 28 days. Data are mean ± SE. ***p < 0.001 vs control. ADR adriamycin, bmMSC bone marrow-derived mesenchymal stromal cell, CM-ucMSC conditioned medium obtained from umbilical cord-derived mesenchymal stromal cell, kPSC kidney perivascular stromal cell

Back to article page